Sign up to save your podcasts
Or
Share COVID-19 Miniseries Episode 36: A Comprehensive Update on COVID-19
Share to email
Share to Facebook
Share to X
Share to email
Share to Facebook
Share to X
Or
COVID-19 Miniseries Episode 36: A Comprehensive Update on COVID-19
This episode was recorded on June 5, 2020.
To claim credit visit: https://ce.mayo.edu/covid19podcast
Guest: Raymund R. Razonable, M.D. (@RazonableMD)
Host: Amit K. Ghosh, M.D., M.B.A. (@AmitGhosh006)
Up to about 50% of people infected with SARS-CoV-2 are asymptomatic spreaders. About 80% of those who are symptomatic, developing COVID-19, have mild disease displaying dry cough, fever, and fatigue. The resulting 20% of symptomatic patients accounts for those who develop progressive respiratory distress and sometimes multi-organ failure, among other complications. We’re learning more about anosmia, cardiac injury, and “COVID-toes.” What’s known about COVID-19 and SARS-CoV-2 continues to evolve. Dr. Raymund Razonable walks through a recently published update on the management of COVID-19.
Time Stamps:
1:18 - New signs and symptoms of COVID-19.
3:30 - Testing characteristics (sensitivity, specificity, and indications) of the molecular and serologic testing for SARS-CoV-2
6:22 - Risk factors and the prediction of disease progression for patients hospitalized with COVID-19
9:28 - Hyper-inflammatory syndrome and progression to multi-system organ failure syndrome
10:45 - Multisystem inflammatory syndrome in children (MIS-C)
11:22 - Cardiac complications - 3 factors
12:50 - Diagnosis and treatment of co-infection in hospitalized patients (COVID-19 and flu, COVID-19 and pneumonia)
16:31 - Evidence-based treatment based on the 3 phases of COVID-19 viremic phase, pneumonic phase, hyperinflammation phase
18:06 - Remdesivir update
21:00 - Hydroxychloroquine update
23:25 - Favipiravir and lopinavir-ritonavir update
23:53 - Treatment of the hyperinflammatory phase (sarilumab, tocilizumab, lenzilumab, anakinra,)
27:13 - Convalescent plasma
28:04 - Discharge and social determinants of health
33:40 - Telehealth and remote monitoring
35:40 - Health disparities and telehealth
37:47 - What’s the next development Infectious Disease specialists are looking for in relation to the COVID-19 pandemic?
See the article here:
A Collaborative Multidisciplinary Approach to the Management of Coronavirus Disease-19 in the Hospital Setting https://doi.org/10.1016/j.mayocp.2020.05.010
AskMayoExpert COVID-19 Resources: https://askmayoexpert.mayoclinic.org/navigator/COVID-19
Connect with the Mayo Clinic’s School of Continuous Professional Development online at https://ce.mayo.edu/ or on Twitter @MayoMedEd.
View all episodes
By Mayo Clinic
4.4
268268 ratings
This episode was recorded on June 5, 2020.
To claim credit visit: https://ce.mayo.edu/covid19podcast
Guest: Raymund R. Razonable, M.D. (@RazonableMD)
Host: Amit K. Ghosh, M.D., M.B.A. (@AmitGhosh006)
Up to about 50% of people infected with SARS-CoV-2 are asymptomatic spreaders. About 80% of those who are symptomatic, developing COVID-19, have mild disease displaying dry cough, fever, and fatigue. The resulting 20% of symptomatic patients accounts for those who develop progressive respiratory distress and sometimes multi-organ failure, among other complications. We’re learning more about anosmia, cardiac injury, and “COVID-toes.” What’s known about COVID-19 and SARS-CoV-2 continues to evolve. Dr. Raymund Razonable walks through a recently published update on the management of COVID-19.
Time Stamps:
1:18 - New signs and symptoms of COVID-19.
3:30 - Testing characteristics (sensitivity, specificity, and indications) of the molecular and serologic testing for SARS-CoV-2
6:22 - Risk factors and the prediction of disease progression for patients hospitalized with COVID-19
9:28 - Hyper-inflammatory syndrome and progression to multi-system organ failure syndrome
10:45 - Multisystem inflammatory syndrome in children (MIS-C)
11:22 - Cardiac complications - 3 factors
12:50 - Diagnosis and treatment of co-infection in hospitalized patients (COVID-19 and flu, COVID-19 and pneumonia)
16:31 - Evidence-based treatment based on the 3 phases of COVID-19 viremic phase, pneumonic phase, hyperinflammation phase
18:06 - Remdesivir update
21:00 - Hydroxychloroquine update
23:25 - Favipiravir and lopinavir-ritonavir update
23:53 - Treatment of the hyperinflammatory phase (sarilumab, tocilizumab, lenzilumab, anakinra,)
27:13 - Convalescent plasma
28:04 - Discharge and social determinants of health
33:40 - Telehealth and remote monitoring
35:40 - Health disparities and telehealth
37:47 - What’s the next development Infectious Disease specialists are looking for in relation to the COVID-19 pandemic?
See the article here:
A Collaborative Multidisciplinary Approach to the Management of Coronavirus Disease-19 in the Hospital Setting https://doi.org/10.1016/j.mayocp.2020.05.010
AskMayoExpert COVID-19 Resources: https://askmayoexpert.mayoclinic.org/navigator/COVID-19
Connect with the Mayo Clinic’s School of Continuous Professional Development online at https://ce.mayo.edu/ or on Twitter @MayoMedEd.
More shows like Mayo Clinic Talks
View all
JAMA Editors' Summary
137 Listeners
NEJM This Week
320 Listeners
AFP: American Family Physician Podcast
700 Listeners
JAMA Clinical Reviews
497 Listeners
Core EM - Emergency Medicine Podcast
250 Listeners
Frankly Speaking About Family Medicine
259 Listeners
The Curbsiders Internal Medicine Podcast
3,343 Listeners
Core IM | Internal Medicine Podcast
1,156 Listeners
Annals On Call Podcast
195 Listeners
JAMA Medical News
90 Listeners
The Clinical Problem Solvers
513 Listeners
Harrison's PodClass: Internal Medicine Cases and Board Prep
364 Listeners
Mayo Clinic Educator's Central
12 Listeners
Run the List
253 Listeners
Simply PM&R
18 Listeners
GRIT in Medicine
15 Listeners
Mayo Clinic Employee Experiences
9 Listeners
Cardionerds: A Cardiology Podcast
430 Listeners
The Curious Clinicians
371 Listeners
Mayo Clinic Pharmacy Grand Rounds
45 Listeners
Mayo Clinic Orthopedic Surgery
14 Listeners